Wu and colleagues (2019) revealed that, with the appropriate siRNA or by the suppression of its function with the specific inhibitor SP2509, KDM1A knockdown increased the efficiency of regorafenib, a second-line agent that targets and inhibits tyrosine kinase receptors [72] in HCC cells and its cytotoxic and apoptotic effects suppressing the proliferation of HCC cells [69]. Here, KDM1A is linked to hepatocellular carcinoma.